Author Archives: Margarida Azevedo, MSc

Dosing Completed in Phase 1 Study of GTP-004 for Myasthenia Gravis Treatment Side Effects

Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy’s developer, GT Biopharma, announced. Preliminary results suggest that GTP-004 enables the safe and well-tolerated administration…

Alexion Receives Extended Patent in Japan for Soliris (Eculizumab)

The Japanese Patent Office (JPO) has issued a new patent for the composition of eculizumab, marketed as Soliris by Alexion Pharmaceuticals, and its pharmaceutical formulations until 2027. Alexion is currently pursuing a patent for additional indications of Soliris, including for the treatment of anti-acetylcholine receptor (AchR) antibody-positive generalized…

argenx Doses First Subject in Study Evaluating Subcutaneous ARGX-113 for Autoimmune Diseases

The first participant has been dosed in a Phase 1 clinical trial evaluating  argenx‘s subcutaneous formulation of ARGX-113 in healthy volunteers. ARGX-113 is an investigational antibody designed for the treatment of patients with severe autoimmune diseases associated with high levels of harmful immunoglobulin G (IgG) antibodies, such as myasthenia gravis (MG).

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.